Introduction 32
Overfat is strongly associated with insulin resistance and chronic inflammation, as well as 33 hypertension, dyslipidemia, cardiovascular diseases (for instance, coronary heart disease and 34 stroke), cancer, type 2 diabetes, gallbladder disease, osteoarthritis, gout, and sleep apnea ("Obesity: 35
Preventing and Managing the Global Epidemic. Report of a Who Consultation" 2000). However, 36 excess body fat not always appears to be associated with cardiometabolic abnormalities. This 37 statement came from observations that some subjects have normal weight but display excessive 38 body fat percent and cardiometabolic dysfunction (metabolically obese normal weight, MONW), 39
and there are also metabolically healthy but obese (MHO) subjects, that are overfat but have no 40 signs of cardiometabolic dysfunction (Ruderman, et al. 1998 ). Regardless of body weight and body 41 mass index, excessive body fat is associated with cardiometabolic dysfunction. The earliest signs of 42 cardiometabolic dysfunction are excessive body fat, insulin resistance, and chronic low-grade 43 systemic inflammation (Maffetone, Rivera-Dominguez, and Laursen 2017). 44
Individuals without obesity but with dyslipidemia and metabolic abnormalities have also been 45 termed as normal weight dyslipidemia (NWD) (Ipsen, Tveden-Nyborg, and Lykkesfeldt 2016). This 46 population has an increased risk of developing nonalcoholic fatty liver disease (NAFLD), 47 cardiovascular disease and type 2 diabetes (Pagadala and McCullough 2012; Ruderman, et al. 48 1998). As the liver regulates lipid metabolism and plasma lipid levels, it plays a significant role in 49 turning an unhealthy diet and lifestyle into an unbalanced metabolic profile. The product of fasting 50 triglycerides and glucose (TyG) is a useful index to assess both insulin resistance and hepatic 51 steatosis/nonalcoholic steatohepatitis (NASH) in apparently normal subjects (Simental-Mendía, et 52 al. 2016; Simental-Mendía, Rodríguez-Morán, and Guerrero-Romero 2008). Thus, it could be used 53 as an additional early marker of metabolic dysfunction in MONW individuals. 54
The liver and the white adipose tissue (WAT) continuously exchange very low-density lipoproteins 55 (VLDL) and free fatty acids (FFA) to store (WAT) and distribute (liver) energy. In obesity, the liver 56
Care and Use of Laboratory Animals (US NIH Publication N° 85-23. Revised 1996) (Kilkenny, et 81 al. 2010) . Male C57BL/6 mice at two months of age were obtained from colonies maintained at the 82 Federal Fluminense University and kept under standard conditions (12 h light/dark cycles, 21±2ºC, 83 humidity 60±10% and air exhaustion cycle 15 min/h). 84
At three months old, mice were randomly allocated into three groups according to the diet offered 85 (n=10-11/group). Control group received a purified diet according to AIN-93M standards (Reeves, 86 Nielsen, and Fahey 1993), and the other two groups received isoenergetic modified AIN-93M diets 87 rich in glucose or fructose (3.81 kcal/g), acquired from Pragsolucoes (Jau, Sao Paulo, Brazil). Both 88 glucose and fructose diets were rich in simple carbohydrates since they have lower complex 89 carbohydrate content (corn starch) and sucrose was removed ( On the day of euthanasia, blood was obtained from awake 6-hour fasted mice by milking the tail 96 after a little incision on its tip and plasma glucose was assessed using a glucometer (One Touch 97 Ultra, Johnson& Johnson, SP, Brazil). Mice were then deeply anesthetized with ketamine 100.0 98 mg/kg (Francotar ® , Virbac, Brazil) and xylazine 10.0 mg/kg ip (Virbaxyl 2% ® , Virbac, Brazil), and 99 the heart was exposed for blood collection (right atrium). Blood was allowed to clot, centrifuged 100
(1,500 x g) and the serum was stored at -80°C for total cholesterol, HDL and triglyceride (TG) 101 colorimetric assay (cat#K083, #K071and K117 respectively, Bioclin, Quibasa, Belo Horizonte, 102
Minas Gerais, BR) and insulin Elisa assay (cat#EZRMI-13K, Merck Millipore, Billerica, MA, 103 EUA) according to manufacturer's instructions. Insulin resistance was evaluated by the homeostatic 104 model assessment, where HOMA-IR = [insulin (µU/mL) x glucose (mmol/L)]/22.5 (Matthews, et 105 al. 1985) and hepatic TG content was determined as described elsewhere (Gonçalves, et al. 2017 
Adipocyte morphometry 119
Digital images were obtained from histological sections using a Leica DMRBE microscope 120 (Wetzlar, German) coupled to a video camera Kappa (Gleichen, German). Morphometry was 121 performed in the Image-Pro® Plus software v. 5.0 (Media Cybernetics, Silver Spring, MD, USA). 122
In the interscapular BAT, eight nonconsecutive images were acquired to assess brown adipocyte 123 diameter, lipid droplet (LD) diameter, and the percentage of tissue area occupied by LD. For lipid 124 area, a selection tool was used to mark the pixels that represented lipid droplets. The selection was 125 segmented in a new digital image in black and white, where the white color represented the LD, and 126 the black color represented the remaining tissue. Then, the area occupied by the white color was 127 quantified through the image histogram tool. In the three WAT depots studied, we assessed 128 adipocyte diameter by measuring their smallest and largest diameters, as previously described 129 Results 138
Early signs of fructose overfeeding: Body fat redistribution without body weight gain 139
Despite glucose and fructose diets were isoenergetic compared to the control diet, Table 1 shows 140 that cumulative food intake (FI) in fructose group was 10% lower than the control group (P<0.02). 141 Additionally, energy efficiency reduced by 63% and 87%, respectively, in glucose and fructose 142 groups (P<0.0001). Neither glucose nor fructose feeding changed body weight, and surprisingly 143 BW gain during the 4 weeks on experimental diets was slowed down, since Δ BW was 63% and 144 88% lower in glucose and fructose groups, respectively, compared to control group (P<0.0001). All 145 white fat depots studied did not vary in weight and did not present adipocyte hypertrophy after 146 glucose or fructose feeding. However, fructose feeding changed body fat distribution, since the ratio 147 between visceral and subcutaneous white fat increased, compared to control group (+15%, 148
P=0.016). 149

Short-term fructose feeding had limited impact on glucose, lipid and hepatic metabolism 150
Thirty days of glucose or fructose feeding did not modulate glucose and lipid metabolism to a great 151 extent, as shown in Table 3 . Glucose group presented a decrese of 41% on blood glucose 152 (P=0.0002) that was followed by an increase in serum (+80%, P<0.0001) and liver (+79%, 153 P=0.0002) triglyceride. On the other hand, fructose only affected total cholesterol (+32%, 154 P=0.002). Insulin resistance, assessed by HOMA-IR and TyG index, was not developed after 4 155 weeks of glucose or fructose feeding. Although fructose feeding increased liver weight, TyG index 156 did not point to the presence of hepatic steatosis (Table 3) , and we also did not find 157 histopathological changes compatible with steatosis (data not shown). 158
Early changes in BAT morphology due to short-term fructose feeding 159 Figure 1 shows that BAT weight remained unchanged after 4 weeks of glucose or fructose feeding. 160
The proportion between BAT and WAT was also not changed, despite a subtle decrease in fructose 161 group. When the amount of visceral WAT is compared to BAT mass, there is a significant decrease 162 of 18% in fructose group compared to control group (P=0.03). We demonstrated in male C57BL/6 mice that short-term fructose feeding did not promote weight 174 gain and adiposity, but WAT fat was redistributed toward visceral depots. Glucose, lipid and 175 hepatic metabolic dysfunction were not yet noticed, with the exception of increased serum total 176 cholesterol and liver weight. The most prominent finding is that fructose feeding changes the 177 proportion between BAT and visceral WAT mass, where the second predominates, and BAT suffers 178 an important premature morphological remodeling due to increased lipid deposition in enlarged 179 intracellular LD, which precedes the onset cardiometabolic abnormalities. 180
In the present study, fructose diminished cumulative food intake, and it likely led to an absence of 181 body weight gain. Tillman et al showed that even when cumulative food intake is increased, no 182 significant increment in final body weight is seen after 14 weeks of 60% fructose feeding (Tillman, 183 et al. 2014 ). They also showed that metabolic rate is increased in the second and ninth weeks of 184 fructose feeding, but at the fourteenth week metabolic rate is similar to control group. We showed 185 through energy efficiency that fructose group gained less weight per energy consumed, compared to 186 control group, and based on Tillman's work we suppose that fructose might have also increased 187 metabolic rate thus maintaining body weight stable. 188 After short-term fructose feeding (4 weeks), C57BL/6 mice still presented neither increased 189 adiposity nor adipocyte hypertrophy, although early signs of fat redistribution were found toward an 190 increased visceral WAT. Long-term fructose feeding is supposed to stimulate adiposity, and 191
Montgomery et al showed increased fat mass on visceral (perigonadal and retroperitoneal) and 192 subcutaneous (inguinal) WAT depots after 8 weeks of fructose feeding (Montgomery, et al. 2015) . 
Insulin resistance includes impairment of fatty acid oxidation and utilization (Kelley and 214
Goodpaster 2001), and hepatic TG content is a strong determinant of hepatic insulin resistance 215 (Marchesini, et al. 1999 ). In the present study, short-term fructose intake increased liver weight 216 despite no signs of hepatic steatosis, as pointed by TG content, TyG index and histopathological 217 analysis (data not shown). Long-term studies have shown that fructose feeding promotes hepatic 218 lipid accumulation of TG and DAG, but not ceramides (Montgomery, et al. 2015) . The phenomenon 219 is due to the upregulation of lipogenic pathways through the elevation of protein contents of both 220 acetyl-CoA carboxylase isoforms (ACC1 and ACC2), fatty acid synthase (FAS) and stearoyl-CoA 221 desaturase (SCD1) (Montgomery, et al. 2015) . 222
Short-term fructose feeding did not change BAT mass, a result found by us and others 223 (Montgomery, et al. 2015) . We have previously shown in female C57BL/6 mice that BAT mass 224 gain is a late event in BAT dysfunction during aging (Gonçalves, et al. 2017 ). We also showed in 225 the present study that average LD size was increased by fructose, but cell size was not affected. We 226 suppose that long-term fructose feeding would result in brown adipocyte hypertrophy, as well as 227 white adipocyte hypertrophy. In aged male C57BL/6 mice, brown adipocyte hypertrophy is 228 associated with BAT morphological abnormalities, lower thermogenesis, and glucose intolerance 229 (Sellayah and Sikder 2014) . LD hypertrophy is due to increased TG storage and, in humans, the TG 230 content of thermogenic supraclavicular fat deposits may be an independent marker of whole-body 231 insulin sensitivity, independent of BAT metabolic activation (Raiko, et al. 2015) . In summary, these 232 data show early modifications of BAT adipocyte architecture by fructose, that will likely lead to 233 metabolic dysfunction in the future, but additional studies are necessary to confirm this hypothesis. The MONW phenotype is characterized by normal weight with increased adiposity and to 248 investigate its underlying mechanisms is of ultimate importance. So far, MONW study in mouse 249 models is limited, and fructose feeding is a potential model to investigate the mechanisms 250 underlying the MONW phenotype. In C57BL/6 mice, it seems that fructose in the drinking water ad 251 libitum can elicit an obesogenic response, but not fructose offered in the food. This very different 252 response in mice to either fed fructose or given fructose liquid was not explored so far. Thus, 253 further studies are necessary to determine the best route for fructose administration (chow or drink 254 water). It is also necessary to investigate how long it takes to develop the MONW phenotype by 255 fructose. Finally, it is important to know which cardiometabolic abnormalities commonly found in 256 MONW humans fructose feed mice would develop (for instance, glucose intolerance, insulin 257 resistance, low-grade inflammation, hypertriglyceridemia, and hypertension), and the time required 258 to see these cardiometabolic changes. 259
Conclusion 260
Short-term fructose feeding redistributes body fat, changes the proportion of BAT to visceral fat, 261 and promotes BAT adverse remodeling. The novelty of the present work is that BAT displays early 262 morphological signs of future metabolic dysfunction before cardiometabolic dysfunction itself, in a 263 model of fructose-fed normal weight mice. A future direction is to determine the timing of 264 cardiometabolic disturbance onset due to fructose overfeeding and BAT adverse remodeling in 265 long-term fructose feeding in male and female C57BL/6 mice. 266
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